Charmacy Pharmaceutical Co Ltd (2289) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Charmacy Pharmaceutical Co Ltd HK$8.51, price HK$5.50, upside +54.9%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Charmacy Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$2.95 – HK$14.90 · fair‑value band HK$6.38 – HK$11.00 · the HK$5.50 price screens below the HK$8.51 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Charmacy Pharmaceutical Co in your weekly email
Every Wednesday you see whether Charmacy Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Charmacy Pharmaceutical Co., Ltd. engages in the pharmaceutical distribution business in the People's Republic of China. It distributes western medicines, Chinese patent medicines, healthcare products, and pharmaceutical products to downstream distributors and retail terminals.
Show more
Charmacy Pharmaceutical Co., Ltd. engages in the pharmaceutical distribution business in the People's Republic of China. It distributes western medicines, Chinese patent medicines, healthcare products, and pharmaceutical products to downstream distributors and retail terminals. The company also offers pharmaceutical product related consulting services; and operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online, make inquires, and payments, etc. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Shantou, the People's Republic of China.
Stock analysis
Charmacy Pharmaceutical Co Ltd (2289) currently trades at HK$5.50, while our model-based Fair Value estimate is HK$8.51, implying the stock looks roughly 35.4% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$30.01 per share, and 22 of the 24 models we run sit above the HK$5.50 price.
Bear case: the Asset-Based group reads lowest at HK$4.47, and 2 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$6.38 (bear) to HK$11.00 (bull), the price of HK$5.50 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Charmacy Pharmaceutical Co Ltd reported revenue of 4.4B CNY in FY2025 versus 3.8B CNY in FY2021, a compound +3.7%/yr. Reported net income was 46.3M CNY in FY2025, compounding +18.9%/yr from FY2021.
Key figures
Market cap HK$788M (≈ $100M) · P/E ratio 14.9 · P/S ratio 0.16 · EPS (TTM) HK$0.2000 · Dividend yield 5.5% · Net margin 1.1% · Return on equity 7.5% · Return on assets (EBIT) 2.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 55%, 2289 screens cheaper than that median.
Fair Value models
Bear HK$6.38Fair Value HK$8.51Bull HK$11.00
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic). Over 10 years: +2.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.9%
Dividend (yield on the price)5.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2.9% vs −0.6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 2%
Compare Charmacy Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+54.9% · Above median
Profitability
Return on equity (TTM)7.5% · Above median
Return on assets2.2% · Below median
Net margin (TTM)1.1% · Below median
Operating margin (TTM)2.8% · Below median
Growth and dividend
Revenue growth6.8% · Above median
Dividend yield (TTM)5.5% · Top 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Charmacy Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2289
Frequently asked questions
Is Charmacy Pharmaceutical Co Ltd (2289) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$8.51 versus a price of HK$5.50, about +55% upside (undervalued).
What is the fair value of 2289?
Our model-based fair value for Charmacy Pharmaceutical Co Ltd is HK$8.51 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$5.50.
What is the quality score of 2289?
Charmacy Pharmaceutical Co Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Charmacy Pharmaceutical Co Ltd (2289)?
Our model-based price target is the fair value of HK$8.51 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$6.38, optimistic scenario HK$11.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Charmacy Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at HK$8.51, about +55% upside versus a price of HK$5.50 (undervalued). Cautious scenario HK$6.38, optimistic scenario HK$11.00. The calculation is refreshed regularly with new filings.
What is the revenue of Charmacy Pharmaceutical Co Ltd (2289)?
Charmacy Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 4.4B CNY (latest available figure, as of Sep 27, 2026).
Does Charmacy Pharmaceutical Co Ltd pay a dividend?
Charmacy Pharmaceutical Co Ltd currently shows a dividend yield of about 5.46% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Charmacy Pharmaceutical Co Ltd (2289)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Charmacy Pharmaceutical Co Ltd it is HK$8.51 per share (as of Sep 27, 2026), against a price of HK$5.50. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Charmacy Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2289 trades below its calculated fair value: price HK$5.50, fair value HK$8.51, a gap of about +55% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2289?
No. The price is what the market pays today (HK$5.50); the fair value is what the company's own numbers justify (HK$8.51). For Charmacy Pharmaceutical Co Ltd the two are HK$3.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Charmacy Pharmaceutical Co Ltd worth?
The market values Charmacy Pharmaceutical Co Ltd at about HK$788M (market capitalisation, as of Sep 27, 2026). Per share that is HK$5.50; our models calculate a fair value of HK$8.51 per share.
What do the bullish and bearish scenarios say about 2289?
Our models span a range for Charmacy Pharmaceutical Co Ltd: cautious scenario HK$6.38, base HK$8.51, optimistic HK$11.00 per share (as of Sep 27, 2026, price HK$5.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2289?
Charmacy Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 14.9 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$8.51 is built from several models across several years. Other multiples: P/B 1.1, P/S 0.2.
How solid is the balance sheet of Charmacy Pharmaceutical Co Ltd (2289)?
Balance-sheet figures for Charmacy Pharmaceutical Co Ltd (as of Sep 27, 2026): return on equity 7.5%, debt of 0.06 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 2289 from its 52-week high?
Charmacy Pharmaceutical Co Ltd trades at HK$5.50, about 25% below its 52-week high of HK$7.30 and 8% above the low of HK$5.11 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$8.51 is for.
Which stocks are comparable to Charmacy Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Charmacy Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$5.50, calculated fair value HK$8.51 (+55%), Quality Score 50/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2289 calculated?
We run Charmacy Pharmaceutical Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$8.51, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Charmacy Pharmaceutical Co Ltd currently trades 35 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Charmacy Pharmaceutical Co Ltd (2289)?
The closing price on Sep 30, 2026 was HK$5.50. Our model-based fair value is HK$8.51, about +55% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Charmacy Pharmaceutical Co Ltd right now?
The price is below even our cautious bear case (HK$6.38). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Charmacy Pharmaceutical Co Ltd (2289) come from?
Earnings per share at Charmacy Pharmaceutical Co Ltd grew +0.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +1.0 %, EBIT margin −4.1 %, tax rate +0.1 %, residual (interest, one-offs) +3.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Charmacy Pharmaceutical Co Ltd
How large is the market capitalisation of Charmacy Pharmaceutical Co Ltd (2289)?
The market capitalisation of Charmacy Pharmaceutical Co Ltd is HK$788M (≈ $100M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Charmacy Pharmaceutical Co Ltd (2289)?
The price-to-sales ratio of Charmacy Pharmaceutical Co Ltd is 0.16 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Charmacy Pharmaceutical Co Ltd (2289)?
Earnings per share at Charmacy Pharmaceutical Co Ltd are HK$0.2000 (price ÷ EPS = P/E 14.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Charmacy Pharmaceutical Co Ltd (2289)?
The dividend yield of Charmacy Pharmaceutical Co Ltd is 5.5% (payout 150%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Charmacy Pharmaceutical Co Ltd (2289)?
The net margin of Charmacy Pharmaceutical Co Ltd is 1.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Charmacy Pharmaceutical Co Ltd (2289)?
The return on equity (ROE) of Charmacy Pharmaceutical Co Ltd is 7.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Charmacy Pharmaceutical Co Ltd (2289)?
On an EBIT basis the return on assets of Charmacy Pharmaceutical Co Ltd is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Charmacy Pharmaceutical Co Ltd (2289)?
The operating margin of Charmacy Pharmaceutical Co Ltd is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Charmacy Pharmaceutical Co Ltd (2289)?
Revenue at Charmacy Pharmaceutical Co Ltd is growing +6.8% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Charmacy Pharmaceutical Co Ltd (2289)?
Earnings per share at Charmacy Pharmaceutical Co Ltd are growing −7.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Charmacy Pharmaceutical Co Ltd (2289) generate?
The free cash flow of Charmacy Pharmaceutical Co Ltd is 263M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Charmacy Pharmaceutical Co Ltd (2289) carry?
The net debt of Charmacy Pharmaceutical Co Ltd is 1.3B CNY (fiscal year 2025, ≈ 5.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Charmacy Pharmaceutical Co Ltd in the live analysis
One click puts Charmacy Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
